Abeprazan (DWP14012) 是一种钾竞争性酸 (potassium-competitive acid) 阻滞剂。Abeprazan 通过可逆的钾竞争性离子结合抑制 H+，K+- ATPase，而无需酸激活。Abeprazan 是一种潜在的质子泵抑制剂，用于研究与酸相关的疾病。
| 生物活性 |
Abeprazan (DWP14012) is a potassium-competitive acid blocker. Abeprazan inhibits H, K- ATPase by reversible potassium-competitive ionic binding with no acid activation required. Abeprazan is developed as a potential alternative to proton pump inhibitor for the treatment of acid-related diseases. |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 体外研究 |
The mechanism of action of Abeprazan is reversibly binding to H, K‐ATPase, and, unlike that of PPIs, does not require acidic environment for drug activation. |
||||||||||||
| 体内研究 |
DWP14012 inhibited acid secretion in a dose-dependent manner and the inhibition of gastric acid secretion was equal to or greater than that of vonoprazan, a previously approved P-CAB, in various in vivo studies using pylorus-ligated rats, lumen-perfused rat models and heidenhain pouch dog models.
|
||||||||||||
| 分子式 |
C19H17F3N2O3S
|
||||||||||||
| 分子量 |
410.41
|
||||||||||||
| CAS号 |
1902954-60-2
|
||||||||||||
| 运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||
| 储存方式 |
|
||||||||||||
| 临床试验 |
|
纯度： 98%
关注我们
获得KKL MED 最新资讯
咨询热线：
400-881-9290
Data Sheet